Back to top

medical: Archive

Zacks Equity Research

KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives

On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.

FOLDNo Net Change CRMDNegative Net Change KRYSPositive Net Change

Zacks Equity Research

Implied Volatility Surging for Ardent Health Stock Options

Investors need to pay close attention to ARDT stock based on the movements in the options market lately.

ARDTNegative Net Change

Zacks Equity Research

PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates

Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.

FOLDNo Net Change PCRXNegative Net Change CRMDNegative Net Change INDVNegative Net Change

Zacks Equity Research

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

TEVAPositive Net Change RPRXPositive Net Change CRMDNegative Net Change INDVNegative Net Change

Debanjana Dey

Hims & Hers Expands Platform-Led Access to Provider-Directed Care

HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.

MEDPositive Net Change GDRXPositive Net Change HIMSPositive Net Change

Zacks Equity Research

GeneDx Partners With Komodo Health to Advance Rare Disease Research

WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.

BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change WGSNegative Net Change

Zacks Equity Research

Exelixis Posts Preliminary '25 Results, Issues '26 Outlook

EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.

RHHBYNegative Net Change EXELPositive Net Change FOLDNo Net Change CRMDNegative Net Change

Zacks Equity Research

INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced

Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.

INSMNegative Net Change CRMDNegative Net Change KROSNegative Net Change

Zacks Equity Research

RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models

Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.

CRLNegative Net Change VCYTPositive Net Change CDNAPositive Net Change RVTYNegative Net Change

Santanu Roy

Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus

Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.

ACNPositive Net Change MMMPositive Net Change SBUXPositive Net Change FORMPositive Net Change ULTANegative Net Change HIIPositive Net Change AMKRNegative Net Change MTDPositive Net Change FIVEPositive Net Change NOBLPositive Net Change FIGSPositive Net Change INDVNegative Net Change

Aparajita Dutta

Buy These 5 Dividend Growth Stocks Amid Conflicting Labor Market Data

Dividend-growth stocks like CAH stand out as labor data sends mixed signals, offering income stability and growth amid economic uncertainty.

CAHPositive Net Change KGCPositive Net Change DCIPositive Net Change WWDPositive Net Change FOXPositive Net Change

Zacks Equity Research

Illumina's New Connected Multiomics Platform Set to Boost Its Stock

ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

BSXNegative Net Change ILMNPositive Net Change IDXXPositive Net Change STEPositive Net Change

Indrajit Bandyopadhyay

3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds

Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.

CAHPositive Net Change MCKPositive Net Change CORPositive Net Change

Sridatri Sarkar

Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?

TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.

EXASPositive Net Change GEHCNegative Net Change TEMPositive Net Change

Zacks Equity Research

Neogen's Q2 Earnings and Revenues Beat Estimates, Stock Climbs

NEOG's Q2 EPS and revenues top estimates, sending shares up 31.6% as the company raises its fiscal 2026 revenue and EBITDA outlook.

MDTNegative Net Change FMSPositive Net Change PBHPositive Net Change NEOGNegative Net Change

Zacks Equity Research

New Strong Buy Stocks for January 12th

ERO, NU, KSS, FLGT and BODI have been added to the Zacks Rank #1 (Strong Buy) List on Jan.12, 2026.

KSSNegative Net Change NUNegative Net Change EROPositive Net Change FLGTPositive Net Change BODIPositive Net Change

Aparajita Dutta

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

AZNNegative Net Change LLYPositive Net Change XLVNegative Net Change VHTNegative Net Change IXJNegative Net Change

Zacks Equity Research

PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities

PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.

BSXNegative Net Change CAHPositive Net Change IDXXPositive Net Change PACBPositive Net Change

Zacks Equity Research

SENS Stock Up as Eversense 365 Enters AID Market With twiist System

Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.

BSXNegative Net Change ISRGNegative Net Change SENSNegative Net Change MEDPPositive Net Change

Zacks Equity Research

J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve

JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

AZNNegative Net Change JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change

Sanghamitra Saha

Here's Why Biotech ETFs Are Rallying Hard

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

IBBNegative Net Change SPYPositive Net Change XBINegative Net Change IDNANegative Net Change CANCNegative Net Change

Zacks Equity Research

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change

Indrajit Bandyopadhyay

3 MedTech Stocks That Crushed the S&P 500 Over the Past Year

TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

CAHPositive Net Change TMDXNegative Net Change KRMDPositive Net Change

Zacks Equity Research

Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.

JNJPositive Net Change BAYRYPositive Net Change FOLDNo Net Change CRMDNegative Net Change

Ekta Bagri

BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change